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Summary Early prediction of respiratory muscle involvement and chronic hypoventi-
lation (CH) in amyotrophic lateral sclerosis (ALS) patients can help to plan mechanical
ventilatory aids and palliative care interventions well before respiratory failure occurs.
To describe the natural history of the progressive pulmonary dysfunction leading to CH,
and to identify potential parameters associated with its development in ALS, we
prospectively followed 38 ALS patients up to 26 months, starting from their first
presentation at our Clinic. At study entry, median FVC was 87% (interquartile range:
72–104%) and declined by 10% after 6 months (range: 2–49%), showing a very high inter-ee front matter & 2005
med.2005.09.035
ing author. Tel: +39 091
ess: danielelococo@yahpatient variability. Over the 26-months follow-up, 19 patients (50%) presented CH in the
first 12 months, and eight patients (21%) developed CH in the remaining 14 months of
the study. The remaining 29% of patients did not show signs of CH during the whole
period of observation. In the Cox model, the category of disease progression (rapid vs.
intermediate and slow), assessed using the Appel ALS Rating Scale (AARS) in the first 3
months after presentation, was the only variable associated with a significantly
increased likelihood of CH. We conclude that CH can occur within 1 year from
presentation in a great proportion of patients, independently from their initial
respiratory status. Including the patients in specific categories of early disease
progression, as assessed with the AARS, could be a sensitive method to identify patients
with different risk of developing CH, and may help physicians to more efficiently plan
the frequencies of respiratory evaluations, initiate mechanical ventilation and discuss
advance directives with the patients and their caregivers.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserve
6555158.
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Amyotrophic lateral sclerosis (ALS) is a devastating
neurodegenerative disease affecting primarily the
large motoneurons in the ventral spinal cord,
brainstem and motor cortex. The degeneration of
these cells leads to progressive weakness and
atrophy of the skeletal muscles and, ultimately,
to paralysis and death, usually as the result of
respiratory failure.1
About 2–3% of ALS patients present initially with
respiratory failure before or at the same time as
manifesting symptoms in the limbs or bulbar
territory. In the rest of the patients, pulmonary
function declines progressively during the course of
the disease, but the rate of decline varies
substantially among them2–4; moreover some pa-
tients may demonstrate precipitous and unex-
pected respiratory failure, making difficult the
prediction of the course of respiratory insuffi-
ciency.5 Thus, in clinical practice, serial and regular
respiratory evaluations are necessary to guide
patient’s management and for monitoring the
decline of pulmonary function.6
When patients show signs of chronic hypoventila-
tion (CH), non-invasive ventilation (NIV) is recom-
mended as an effective initial therapy.6,7 There is
in fact strong evidence that NIV can improve
symptoms and prolongs survival.8–10
Early prediction of small subgroups of patients at
great risk of CH development would be of value for
counseling of these patients and their families in
making decisions about ventilatory support and
might help physicians more efficiently plan medical
interventions.
The aims of this study were to describe the
natural history of progressive pulmonary dysfunc-
tion leading to CH in an ALS clinic population, and
to identify potential parameters significantly asso-
ciated with its development, that could be taken as
predictors for the need for respiratory assistance.Patients and methods
Consecutive ALS patients, attending to the ALS
Clinic of the University of Palermo, were included
in the study from October 1999 to December 2001.
Patients were diagnosed as probable or definite ALS
according to the El-Escorial WFN revised criteria.11
Demographic and clinical features of presenta-
tion of all the patients were recorded, including:
age, gender, date of first symptom and area
of onset, body mass index (BMI). Functional
impairment due to ALS was evaluated using theALS-Functional Rating Scale12 (ALS-FRS), and the
Appel ALS Rating Scale13 (AARS). ALS-FRS is a 10-
item, 40-point scale that measures bulbar, upper
extremity, lower extremity, and respiratory func-
tions. Scores range from 0 (severe impairment) to
40 (normal functioning). AARS is a comprehensive
rating scale providing a reliable and reproducible
quantitative assessment of the clinical course of
ALS. Total AARS score includes five group scores
(bulbar, respiratory, muscle strength, upper and
lower extremity function), and each of these
groups is divided into subgroups with a score of 6
points for normal persons and 30–36 points for
patients with maximal dysfunction. The total score
ranges from 30 (normal functioning) to 164 (max-
imal dysfunction). According to AARS,13,14 patients
were stratified in three subgroups with different
rates of disease progression (rapid: slope of the
total ALS score44 points per month; intermediate:
between 2 and 4 points per month; slow:o2 points
per month), after an initial evaluation period of 3
months (unpublished observations).
Pulmonary function was evaluated in all patients
at presentation, each month for the first 3 months,
and then every 1–3 months. Forced vital capacity
(FVC), expressed in liters and as percentage of the
predicted value (FVC%) for age, height, weight, and
gender, was measured using a Compact II spirom-
eter (Vitalograph). Daytime arterial blood gases
while breathing room air were also measured.
Nocturnal oximetry was evaluated every 4 months;
mean and nadir oxygen saturation (SaO2) and the
proportion of time spent with SaO2o88% were
determined. Maximal static inspiratory and expira-
tory mouth pressures (MIP and MEP) were not
recorded because many patients could not perform
these tests as the disease progressed. Ability to
cough was measured with a hand-held peak flow-
meter. The slope of FVC decline (FVC slope) was
calculated after the first 3 months of observation as
slope of regression line by the least-squares
method.
CH was diagnosed, in accordance with published
guidelines,6,7 when patient presented respiratory
symptoms (such as dyspnea, morning headache,
daytime hypersomnolence, etc.) and/or one of the
following: (i) FVCo50% of predicted value;
(ii) PaCO2X45mmHg; (iii) nocturnal desaturation
(defined as SaO2o88% for 5 consecutive minutes).
All the patients were followed up to 26 months
and the occurrence of CH was recorded as study
end-point.
NIV was offered to all the patients that devel-
oped CH. NIV was established in the hospital using a
bilevel positive-pressure ventilator (BiPAP) in spon-
taneous-timed mode, with pressures adjusted in
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efficiency of ventilation. Patients were instructed
to use NIV for as long as tolerated after retiring to
bed and as necessary in the daytime. To maximize
compliance, alternate interfaces were used as
necessary (nasal, oronasal and total facemasks
and mouthpieces), nasal steroids sprays were used
for nasal congestion, and suction devices for
clearance of secretions. All patients were taught
assisted cough techniques (including mechanical
insufflator–exsufflator) by an experienced respira-
tory physiotherapist. All the patients that started
treatment with NIV were subsequently followed to
death or tracheostomy.
Data are expressed as mean7standard deviation
(SD) or median (interquartile range) for variables
not-normally distributed. The generalised Fisher
exact (Fisher–Freeman–Halton) test was performed
as a test of independence among categorical
variables. One-way ANOVA was performed to
compare the mean age among groups. Kruskal–
Wallis test was used to compare other quantitative
variables among groups and, when the test resulted
significant, multiple comparisons were made using
the Dwass–Steel–Critchlow–Fligner method. Equal-
ity of variance among groups was tested by the
squared ranks test. The two-sided Cuzick’s test for
trend was used to eventually point out a data trend
from the slow ALS group toward the rapid one.
Kaplan–Meier analysis was performed to estimate
event-free rates and hazard from data. Plots of
Kaplan–Meier functions were obtained. Log-Rank
and Wilcoxon tests were performed for comparing
Kaplan–Meier curves; when appropriate, hazard
ratio, chi-square (w2) for equivalence of events, andTable 1 Characteristics of the 38 ALS patients, and t
progression, according to the Appel ALS Rating Scale (AAR
Characteristic Total ALS
patients
AARS
Slow
No of ALS patients 38 14
Gender (F/M ratio) 0.65 0.6
Age (mean years7SD) 59.8711.8 60.8
ALS onset (Bulbar/Spinal ratio) 0.36 0.17
ALS-Functional Rating Scale score 30 (26–33) 30 (2
Appel ALS Rating Scale score 66 (52–75) 60 (4
Baseline FVC% 87 (72–104) 92 (7
Time from disease onset to study
entry (months)
15 (10–36) 37 (1
Data are expressed as median (interquartile range).
yStatistically significant (P ¼ 0.0311) versus intermediate AARS
zStatistically significant (P ¼ 0.0046) versus slow AARS categorw2 for trend were computed. Cox regression was
performed to investigate the effect of some
variables upon the time-related events; when
appropriate, risk ratio and 95% confidence interval
(95% CI) were calculated. A P value o0.05 was
considered statistically significant.Results
Demographic and clinical characteristics of
the ALS patients
A total of 38 ALS patients were included in the
study. Demographic and clinical features of pre-
sentation are summarized in Table 1. The male-to-
female gender distribution was 1.5:1, and limb
onset vs. bulbar onset was 2.8:1. The age of
patients averaged 59.8 years (SD+11.8 years). The
median delay from first symptom to study entry was
15 months. Median ALS-FRS score was 30, median
AARS score was 66. No patient presented obstruc-
tive sleep apnea syndrome or other chronic
respiratory diseases. Furthermore, accordingly to
Haverkamp et al.14 and our previous unpublished
observations, patients were divided into three
subgroups by their rate of disease progression after
three clinical examinations performed in the first 3
months after presentation. In accordance with
previous reports,13,14 14 patients (36.8%) were
identified as slow, 10 patients (26.3%) as inter-
mediate, and 14 (36.8%) as rapid. There were no
significant differences in the clinical and demo-
graphic characteristics among the patients of theheir distribution in the three categories of disease
S).
categories
Intermediate Rapid P
10 14 /
1.0 0.6 0.7668
713.3 60.3713.6 58.479.5 0.858
0.25 0.75 0.2638
7–33) 30 (26–33) 31 (25–32) 0.8586
6–72) 68 (58–75) 66 (58–79) 0.529
5–104) 96.5
(77–120)
79 (63–101) 0.1892
4–78) 19.5 (12–30) 11 (9–13)y,z 0.0023
category.
y.
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disease length from onset to study entry (11 months
for rapid, 19.5 months for intermediate, and 37
months for slow category; Po0:003) (Table 1).Months from study entry    
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Figure 1 Relationship between the absence of chronic
hypoventilation (CH) and the time from study entry in the
whole group of patients. Kaplan–Meier curve depicts the
proportion of patients without CH according to the time
since study entry (initial number of patients: 38).Natural history of the progressive pulmonary
dysfunction leading to CH
At study entry, median FVC% was 87 (interquartile
range: 72–104) and declined by 10% after 6 months
(range: 2–49%).
No correlations were found between FVC% at
study entry and age, gender, interval between
disease onset and first evaluation, site of disease
onset, BMI, ALS-FRS score, AARS score, rate of
disease progression, and FVC slope during the first 3
months.
Pulmonary function deterioration as measured by
FVC tended to assume a linear course during the
progression of the disease with a great deal of
inter-patient variability. However, as already re-
ported,3 we could identify an early (and highly
variable in duration) phase of the disease in which
there is no evidence of respiratory deterioration,
and an active phase in which the deterioration
tends to assume a grossly linear pattern of decline.
The considerable variance in deterioration rates
observed among patients and in the duration of the
early phase above described, give explanation
for the observed wide range of FVC% decline at
6 months.
The average CH-free time (time spent between
first evaluation and CH occurrence) of the 38
patients was 12 months (95%CI: 9–20). The occur-
rence of CH in all the patients is shown in Fig. 1;
nineteen patients (50%) showed CH during the first
12 months study period, eight patients (21%)
developed CH during the remaining 14 months of
the study. The remaining 29% of patients did not
show signs of CH during the whole period of
observation. No patient suffered from upper airway
infections, pneumonia or aspirations.
NIV was offered to all the 27 patients that
developed CH. The characteristics of the subjects
at the time of NIV proposal are shown in Table 2. No
patient presented a breathing frequency 421
breaths/min or a peak cough flow below 270 L/
min. Twenty-four patients accepted a trial, and
twenty continued treatment subsequently. Three
patients refused the treatment. Overall, no differ-
ence could be noted in the ability to cope with NIV
treatment among patients belonging to the three
categories of disease progression or with different
severity of bulbar impairment. Median survivalfollowing initiation of NIV was 17 months (inter-
quartile range: 7–22 months).Parameters significantly associated with the
development of CH
Among the patients’ clinical and demographic
characteristics examined (age, gender, time be-
tween disease onset and first evaluation, site of
disease onset, BMI, ALS-FRS score, AARS score, rate
of disease progression in the first 3 months after
presentation, FVC at first evaluation, and FVC slope
during the first three months), we found a very
close agreement between the probability of CH and
the three different groups of disease progression.
All fourteen patients (100%) of the rapid group
showed signs of CH within the first 12 months of
study period (range: 5–12 months) (Fig. 2). Five
patients (20,8%), identified as intermediate or slow,
showed CH during the first 12 months of study, and
eight patients (33,3%) presented CH within the
remaining study period (overall range: 4–23
months) (Fig. 2).
Median CH-free time for the rapid category of
patients was 9 months (95%CI: 7-10), it was 20
months (95% CI: 12–26) for the intermediate
category, and 22 months (95%CI: 19–26) for the
slow category.
Hazard ratio showed a significant lower risk in
slow and intermediate progression groups when
compared with the rapid progression group, 0.15
(95%CI: 0.05–0.42) and 0.31 (95%CI: 0.1–0.94),
respectively. On the contrary, the comparison
between slow and intermediate groups showed a
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Figure 2 Relationship between the Appel ALS Rating Scale (AARS) category, the absence of chronic hypoventilation (CH)
and the time from study entry. Kaplan–Meier curves depict the proportion of patients without CH according to the time
since study entry. The patients (38) are grouped with respect to their AARS category (R ¼ rapid progression, n:14;
I ¼ intermediate progression, n:10; S ¼ slow progression, n:14). CH-free survival differed significantly among the three
groups (Po0.0001 by the Log-Rank test).
Table 3 Risk of chronic hypoventilation in the 38 ALS patients, by Cox regression analysis.
Variable Risk ratio (95% confidence interval) P value
Gender 0.89 (0.37–2.17) 0.8058
Age 1.05 (1.00–1.09) 0.8126
Site of ALS onset 0.95 (0.29–3.12) 0.9356
BMI 1.00 (0.90–1.11) 0.0902
ALS-FRS score 1.16 (0.98–1.37) 0.9826
AARS score 1.05 (0.99–1.11) 0.0825
Rapid AARS category 12.71 (3.51–46.07) 0.0001
Time from disease onset 0.98 (0.96–1.12) 0.0652
FVC slope 0.99 (0.93–1.09) 0.0595
BMI, body mass index; ALS-FRS, ALS-Functional Rating Scale; AARS, Appel ALS Rating Scale; FVC, forced vital capacity.
Development of CH in ALS patients 1033non-significant hazard ratio of 0.49 (95%CI:
0.21–1.16); therefore we cannot assert a significant
difference between these two groups.
By Cox regression, the category of disease
progression (rapid vs. intermediate and slow) was
the only variable that showed a significant risk ratio
(12.71; 95%CI: 3.51–46.07; Po0:0001), when ad-
justed for all the other variables included into the
model (Table 3). All the other characteristics
examined, including site of disease onset, ALS-FRS
score, FVC at first evaluation, time from disease
onset to study entry, and FVC slope during the first
3 months, did not result to be significantly
predictive of CH development. Differently from
the overall rate of disease progression, individualsubscores of the AARS (bulbar, respiratory, muscle
strength, upper and lower extremity function) were
not significantly associated with CH development.
Moreover, Haverkamp et al. 14 in their original work
calculated a model for survival prediction based on
the sum of certain covariates (age, rate of change
of the total AARS score, rate of change of the
respiratory AARS subscore, and the time from first
symptom until the first examination) and the
calculated regression coefficient for that covariate,
and they found the model to fit the observed data
reasonably well. However, we did not calculate
such a risk score since in our Cox regression
analysis, the category of disease progression only
was significantly related to development of CH.
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ALS invariably leads to respiratory muscle paralysis
and respiratory failure. Impaired ventilatory func-
tion can occur early, as well as late, in the course of
the disease, and it is not possible to predict the
rate of its deterioration in the patient with a
normal respiratory function. Serial measures (espe-
cially FVC) are then recommended to guide
management and to determine prognosis, although
there is currently no published data to indicate how
often these patients should be followed.6,15 Thus,
the individual prognosis and prediction of clinically
relevant pulmonary involvement would be of great
value for counseling and management.
In this work, accordingly to previous studies,2–4
we have shown that the overall course of FVC
decline tends to assume a roughly linear course
during the progression of the disease with a highly
variable rate of decline within the group of
patients, after an initial, and variable in time,
steady state. Mean FVC% declined by 10% after 6
months (range 2–49%). The considerable inter-
patient variability in deterioration rates and in
the duration of the early steady phase, give
explanation for the wide range of FVC% decline at
6 months that we observed.
Progressive respiratory insufficiency leads to CH
that is a leading cause of respiratory failure, and
NIV should be offered to all the patients at this
stage of the disease as initial effective treat-
ment.6,7 However, to our knowledge, there is no
study that specifically investigated the timing of CH
development in ALS patients.
In our ALS population, a group of ambulatory
patients referred for the first time to an ALS Clinic,
and that could closely reflect patients encountered
in the clinical practice, 50% of patients showed
signs of CH within the first 12 months follow-up;
during the remaining 14 months of observation,
another 21% of patients presented CH.
Our data clearly show that CH can be a relatively
early event in a great proportion of patients, and
underline the need for careful respiratory assess-
ment since patient’s referral to the Neurologic
consultant. On the contrary, in a recent survey on
current UK practice about NIV use, Bourke et al.
states that a substantial proportion of neurologists
do not assess vital capacity or other indices of
respiratory function in the routine assessment of
ALS patients, and consider symptoms to be the
principal indication for NIV.16
In the present study, we have also shown that the
category of disease progression (rapid vs. inter-
mediate and slow) was the only variable signifi-
cantly associated to the development of CH.Interestingly, all 14 patients of the rapid group,
that represent more than 30% of our and others ALS
populations,13,14 showed signs of CH within the first
12 months of study period, and within 25 months
from disease onset (range 11–25 months), whereas
only five patients (20,8%) of the intermediate or
slow groups, showed CH during the first 12 months
of study. These results confirm the clinical impres-
sion that there are subgroups of patients who
progress faster and develop respiratory impairment
sooner, and now provide tools with which to
quantify this fact.
As already reported,10 the rapidly evolving
patients presented a lower median time from
disease onset to study entry. However, when
included in the Cox regression model as a contin-
uous variable, disease duration to study entry
failed to significantly predict CH occurrence,
suggesting that the category of disease progression
is a more important predictor of CH.
Interestingly, in our study, neither the FVC slope,
obtained after the first 3 months of observation,
the same time needed to classify the patients in the
AARS categories, was a reliable predictor of CH.
This result is surprising, considering the grossly
linear course of the FVC deterioration observed
analyzing longer periods of time, and possibly
reflects low sensitivity of FVC to detect respiratory
changes, particularly in the earlier phase of
ALS,2,5,17,18 in which patients may not have entered
the active phase of deterioration yet. Moreover,
the difficulty of measuring FVC in patients with
bulbar involvement or marked upper motor neuron
problems is well known. Both of these impair
accuracy of FVC determination and may account,
at least in part, for its insensitiveness. Probably,
then, FVC, even if it constitutes one of the five
components of the AARS that we used for predic-
tion, is not the best way to measure decreased
ventilation in these patients, especially those with
a rapid progression course, and clinicians should
not rely too much on it to guide initiation of
ventilatory support, as, on the contrary, it has been
recently shown.19 Furthermore, since we could not
identify any individual subscore of the AARS
(bulbar, respiratory, muscle strength, upper and
lower extremity function) significantly associated
with CH development, we are now evaluating which
of these five parameters of the AARS could have the
best predictive impact on CH in a larger ALS
population.
It is well known that multidisciplinary approach
to ALS (including at least neurologists, pulmonolo-
gists, nurses, and speech, respiratory, and occupa-
tional therapists) represents the best model of care
for these patients.6,15 In this context, a complex,
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Development of CH in ALS patients 1035even if easy to administer (each assessment takes
approximately 20min to complete), rating scale,
such as the AARS could overcome the limitations of
FVC assessments above mentioned, thanks to the
wide range of components (functional and quanti-
tative) included, giving back a complete view of
the patient and thus an highly sensitive and
reproducible assessment.
The slope of the total AARS score has already
been shown to be a significant covariate of survival
in about 80% of patients, even if its ability to
predict outcome is less accurate in patients who
progress very rapidly.14 However, this rating scale
has never been tested in its ability to predict the
need for respiratory assistance in an ALS clinic
population. Our observations, then, might have
prognostic value for the prediction of respiratory
impairment in the individual patient, and have
several implications for ALS patients management,
since achieving a reliable prognosis can enable
focused services to be available earlier and allow a
management plan to be drawn up in anticipation of
the respiratory deterioration.
According to our results, AARS may allow the
recognition of a group of patients (the rapidly
evolving patients) that show higher risk of devel-
oping CH. Major efforts in evaluating respiratory
status in ALS, then, could be focused on rapid
patients, even in the presence of normal pulmonary
function (at least every 1 month); intermediate and
slow patients, in the absence of marked respiratory
involvement, could be evaluated at longer intervals
of time, due to their lower decline rates.
Frequent review of rapid patients might lead to a
better identification of early signs and symptoms of
weakness of the respiratory muscles, avoiding the
stress of frequent testing in patients with slower
decline rates. Appropriate planning of respiratory
assessments can be expected to enhance patient
and family comfort, improve patient outcomes, and
increase the efficiency of health care resource
utilization.
In the last decade, non-invasive mechanical
ventilation has become standard for the therapy
of respiratory failure in ALS. However, patients
often report that it takes considerable time to
learn how to use the equipment and become
comfortable using it for more than short periods
of time.20 Educational and teaching programs,
then, might be arranged for rapid patients before
respiratory weakness occurs, in order to ensure
motivation and to maximize the compliance of
treatment in this group of patients.
Finally, rapid patients and their family, due to
the fast pulmonary function decline they display,
should be informed about future respiratory careearly in their clinical course, soon after diagnosis,
since they are at great risk of either sudden death
or ventilatory dependence without proper advance
planning.
This informed decision-making could allow an
open discussion and a frequent review of the
options such as the patient’s desire to be resusci-
tated in the event of a respiratory arrest, and their
desire to undergo full mechanical ventilation in the
event of incipient respiratory failure without the
pressure of an emergency.
A limitation of our study is that our sample size is
small and this might limit the generalization of our
results, so that other studies are needed to confirm
our results. However, despite our sample size being
small, we achieved significant findings, that stress
the strong correlation between the AARS category
of disease progression and the probability of CH
occurrence.
In conclusion, we have shown that CH can occur
within 1 year from presentation in a great propor-
tion of patients, independently from their initial
clinical and demographic characteristics. Including
the patients in specific categories of disease
progression in early ALS, as assessed with the AARS,
could be a sensitive method to identify patients
with different risk of developing CH, and may help
physicians to more efficiently plan the frequencies
of respiratory evaluations, initiate mechanical
ventilation and discuss advance directives with
the patients and their caregivers.References
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